Forest’s Solomon Holding Firm As Icahn Presses Second Consecutive Proxy Fight
This article was originally published in The Pink Sheet Daily
Executive Summary
In July 9 letter to Icahn, Forest CEO asks why the activist investor hasn’t offered strategic ideas, rather than threaten another fight over board control.
You may also be interested in...
Forest’s Board Grows, As Icahn Gains Second Director’s Seat
Dissident shareholder Carl Icahn will have some influence on the succession process as the New York drugmaker seeks a replacement for its retiring octogenarian CEO. Forest still needs to compensate for the loss of blockbuster antidepressant Lexapro, and could consider a sale or dramatic restructuring.
Carl Icahn’s Partial Victory In Battle For Forest: One Board Seat
Primary care-focused pharma reports that preliminary voting results show former OSI executive Pierre Legault was elected to the Forest board, replacing long-time member and outgoing compensation committee Chairman Dan Goldwasser.
Tudorza’s Delivery System Key To Positioning For COPD Maintenance
Forest Laboratories’ sales representatives will combine marketing for aclidinium, which FDA approved July 24, with their education efforts for Daliresp for COPD exacerbations.